Eyenovia (NASDAQ:EYEN) Announces Quarterly Earnings Results

Eyenovia (NASDAQ:EYEN) released its quarterly earnings data on Tuesday. The company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.13) by $0.02, Zacks reports. Eyenovia had a negative return on equity of 1,197.12% and a negative net margin of 114,639.41%. During the same period last year, the business earned ($0.18) EPS.

Eyenovia Price Performance

Eyenovia stock opened at $0.41 on Thursday. Eyenovia has a 12 month low of $0.37 and a 12 month high of $2.57. The stock’s 50 day moving average is $0.50 and its 200-day moving average is $0.72. The company has a current ratio of 0.46, a quick ratio of 0.27 and a debt-to-equity ratio of 3.72. The company has a market capitalization of $26.10 million, a price-to-earnings ratio of -0.56 and a beta of 1.75.

Wall Street Analyst Weigh In

Several analysts have issued reports on EYEN shares. HC Wainwright restated a “buy” rating and issued a $12.00 price objective on shares of Eyenovia in a research note on Wednesday. William Blair upgraded Eyenovia to a “strong-buy” rating in a research note on Friday, August 30th.

Insider Activity

In other news, CEO Michael M. Rowe bought 50,000 shares of the firm’s stock in a transaction dated Monday, August 26th. The shares were bought at an average price of $0.57 per share, with a total value of $28,500.00. Following the completion of the transaction, the chief executive officer now owns 82,927 shares of the company’s stock, valued at $47,268.39. This trade represents a 100.00 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. 7.10% of the stock is owned by company insiders.

About Eyenovia

Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.